ResMed History: Founding, Growth & Key Milestones

The origins of ResMed date back to 1981 at the University of Sydney in Australia, where Dr. Colin Sullivan invented nasal continuous positive airway pressure (CPAP)—demonstrating that delivering pressurized room air through a nasal mask acted as a pneumatic splint, keeping upper airways open and curing obstructive sleep apnea. Recognizing the immense clinical potential of this discovery, Dr. Peter Farrell, a biomedical engineer and vice president of R&D at Baxter Healthcare, led an investment to license Sullivan's patents. In 1989, Dr. Farrell founded ResMed (short for 'Respiratory Medicine') in Sydney with nine employees to commercialize comfortable, whisper-quiet CPAP machines. The company's early years were characterized by pioneering engineering: replacing bulky industrial blowers with compact, microprocessor-controlled motors and designing ergonomic silicone masks. In 1995, ResMed completed an initial public offering on NASDAQ before dual-listing on the New York Stock Exchange and the Australian Securities Exchange (ASX). In 2014, under CEO Mick Farrell, ResMed executed a radical digital transformation by embedding cellular chips as a standard feature into every single AirSense 10 device, instantaneously creating the world's largest remote patient monitoring network in respiratory medicine. In the decades following its initial founding, ResMed navigated rapid industry evolutions, transitioning from early legacy operating paradigms to modern integrated operations. This sustained focus allowed the company to survive cyclical macroeconomic contractions, outpace regional incumbents, and establish deep institutional trust with demanding stakeholders. Through disciplined capital allocation, continuous internal innovation, and targeted strategic initiatives, ResMed built an enduring competitive moat anchored by proprietary technology, deep domain expertise, and sticky relationships that resist structural disruption.